Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
The company who manufactures new NHS weight loss drug tirzepatide has issued a statement following the death of Scottish ...
Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...
NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...
Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...
Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, ...
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 ...
Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback